data_1w7d_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1w7d _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 . . . . . 0 N--CA 1.48 1.031 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 93.2 m -145.34 127.95 16.13 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.829 0.347 . . . . 0.0 110.172 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.785 ' HA3' ' HG3' ' A' ' 52' ' ' LYS . . . 113.18 -47.15 1.07 Allowed Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -172.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.3 t0 69.89 -90.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.469 0.708 . . . . 0.0 111.047 168.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.422 HD13 ' H ' ' A' ' 25' ' ' ILE . 3.7 mp -73.37 -48.89 40.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.199 0.523 . . . . 0.0 109.978 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.921 HG12 ' HA ' ' A' ' 48' ' ' VAL . 11.0 m -72.54 -32.36 41.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.17 -172.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.522 ' HB3' ' HA2' ' A' ' 23' ' ' GLY . 11.3 pt-20 -66.49 -12.99 60.2 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.877 0.37 . . . . 0.0 111.002 -172.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.816 HG22 ' HB3' ' A' ' 39' ' ' LEU . 30.8 m -48.52 -40.82 28.15 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.389 177.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -44.69 -34.71 2.33 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 173.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 m -65.86 -41.04 92.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.053 0.454 . . . . 0.0 110.943 -179.018 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.01 -76.31 1.06 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.597 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.9 ' HB1' ' HA ' ' A' ' 36' ' ' THR . . . 54.32 77.48 0.19 Allowed 'General case' 0 C--O 1.232 0.146 0 C-N-CA 123.148 0.579 . . . . 0.0 111.848 177.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.78 -44.58 1.63 Allowed Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.8 p -89.46 -40.26 12.81 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.294 -0.453 . . . . 0.0 110.4 177.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.497 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 64.7 m-85 -103.36 33.9 3.14 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.296 0.57 . . . . 0.0 110.626 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.9 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . 15.2 t -67.92 -32.06 72.25 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.884 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.2 t -90.19 0.98 56.92 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.887 0.329 . . . . 0.0 111.887 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.415 ' HB2' ' CZ ' ' A' ' 67' ' ' PHE . 1.5 tm? -138.97 -66.38 0.47 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 119.988 -0.685 . . . . 0.0 112.395 -175.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.816 ' HB3' HG22 ' A' ' 28' ' ' THR . 12.0 tp -78.91 -12.46 60.03 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -166.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.4 t -60.23 -28.19 67.81 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 109.265 169.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.28 -6.52 58.97 Favored 'General case' 0 C--O 1.215 -0.719 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.825 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.67 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -61.74 -52.98 62.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.391 0.615 . . . . 0.0 109.812 178.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.473 ' HA ' ' HB ' ' A' ' 48' ' ' VAL . 4.0 tp10 -69.77 -49.39 53.38 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-O 121.321 0.581 . . . . 0.0 109.565 172.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.71 -9.17 58.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 -165.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.631 ' HB1' HD11 ' A' ' 47' ' ' LEU . . . -96.64 3.35 52.56 Favored 'General case' 0 C--N 1.323 -0.563 0 O-C-N 121.957 -0.464 . . . . 0.0 110.443 175.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.58 21.72 49.95 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.969 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.67 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 9.9 mp -94.94 -5.95 43.61 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.229 0.538 . . . . 0.0 109.85 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.921 ' HA ' HG12 ' A' ' 26' ' ' VAL . 2.7 p -54.98 -50.91 58.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.392 -0.822 . . . . 0.0 112.194 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.489 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 24.1 t70 -63.98 -21.4 66.48 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.053 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.4 m -87.49 -52.99 5.04 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.83 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.446 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 78.1 mt -80.12 -46.97 15.5 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.011 0.434 . . . . 0.0 111.719 -172.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.785 ' HG3' ' HA3' ' A' ' 23' ' ' GLY . 11.7 tttt -93.26 -9.53 38.78 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.332 0.587 . . . . 0.0 110.179 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 49' ' ' ASP . . . -85.67 0.41 88.1 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.373 -170.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -132.68 -68.46 0.6 Allowed 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.873 176.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.99 -124.17 1.07 Allowed Glycine 0 N--CA 1.44 -1.077 0 C-N-CA 120.356 -0.926 . . . . 0.0 111.471 -172.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HB2' ' CA ' ' A' ' 98' ' ' GLY . 19.5 Cg_endo -60.16 120.75 8.7 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.64 1.56 . . . . 0.0 111.831 -177.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' O ' ' HA2' ' A' ' 144' ' ' GLY . 9.9 m-85 -149.2 134.81 18.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.238 174.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.93 HG22 ' HB ' ' A' ' 96' ' ' VAL . 0.4 OUTLIER -118.18 122.52 43.22 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.012 -174.384 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 31.1 m -127.99 139.27 52.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.579 -178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -79.86 92.29 5.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.635 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -91.46 112.16 52.77 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.761 ' HB3' HG13 ' A' ' 149' ' ' ILE . 59.8 Cg_endo -80.18 145.41 17.18 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 121.943 1.762 . . . . 0.0 111.64 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.6 t -80.83 171.06 15.49 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.693 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -60.39 -30.02 69.33 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.338 0.59 . . . . 0.0 110.203 178.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.37 -15.32 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.172 178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.96 -36.56 49.01 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.124 0.488 . . . . 0.0 110.47 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.51 ' HE2' ' HB3' ' A' ' 78' ' ' LEU . 14.6 m-85 -68.68 -26.64 65.4 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.634 174.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.38 -13.23 59.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.411 175.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.411 ' C ' ' HD3' ' A' ' 71' ' ' PRO . . . -75.44 -44.26 45.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.118 176.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.466 ' N ' HD21 ' A' ' 70' ' ' LEU . 0.5 OUTLIER -119.27 74.6 15.28 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-O 121.393 0.616 . . . . 0.0 110.334 172.179 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.414 ' HA ' ' CG1' ' A' ' 75' ' ' VAL . 60.9 Cg_endo -94.62 7.9 2.18 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.386 2.724 . . . . 0.0 113.042 -175.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -57.54 -60.26 3.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.935 0.397 . . . . 0.0 110.371 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.71 -10.35 0.18 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.014 175.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.3 m -71.47 -39.23 71.05 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.831 0.316 . . . . 0.0 110.682 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.423 ' O ' ' HB2' ' A' ' 79' ' ' LEU . 10.2 p -68.34 -31.37 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . 0.581 ' O ' ' HG2' ' A' ' 80' ' ' LYS . 12.2 tp10 -68.11 -46.64 70.37 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -57.83 -47.22 83.28 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.209 0.528 . . . . 0.0 110.39 176.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.51 ' HB3' ' HE2' ' A' ' 67' ' ' PHE . 10.6 mp -77.14 -8.19 57.08 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.684 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 75' ' ' VAL . 28.7 tp -95.31 -21.14 18.6 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.249 0.547 . . . . 0.0 109.812 175.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.581 ' HG2' ' O ' ' A' ' 76' ' ' GLU . 73.1 mmtt -71.96 136.82 82.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.138 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.22 -16.68 18.06 Favored 'Trans proline' 0 N--CA 1.474 0.368 0 C-N-CA 122.99 2.46 . . . . 0.0 112.343 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -65.1 -31.99 73.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.588 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.534 ' O ' ' HG ' ' A' ' 87' ' ' LEU . 4.1 p30 -73.77 -36.58 65.11 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.816 -0.354 . . . . 0.0 111.802 -170.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.432 ' HA ' HD11 ' A' ' 87' ' ' LEU . 14.7 pttm -68.14 -25.56 65.34 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.997 -176.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.413 ' O ' ' HB ' ' A' ' 88' ' ' THR . 5.0 mm-40 -69.84 -39.44 76.42 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.816 178.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.441 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 12.1 ptmm? -81.08 -23.31 38.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.895 178.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 83' ' ' ASN . 57.2 mt -61.41 -35.69 78.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 171.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.533 ' O ' HD23 ' A' ' 91' ' ' LEU . 51.7 m -54.4 -42.65 70.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.18 0.514 . . . . 0.0 110.355 172.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -74.11 -44.02 55.39 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.718 178.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.486 HD12 ' HG2' ' A' ' 155' ' ' PRO . 1.5 tp -97.77 2.61 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.882 -162.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 88' ' ' THR . 2.5 pt? -49.98 -37.04 30.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.971 -176.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.526 ' HB ' ' CA ' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -61.02 -26.12 67.39 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.355 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.499 ' CD2' ' HA ' ' A' ' 154' ' ' MET . 41.2 t80 -94.34 -6.98 43.08 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.421 0.629 . . . . 0.0 110.333 -178.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -106.93 -21.85 12.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.585 0.707 . . . . 0.0 109.17 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 93.4 t -96.88 121.12 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.778 176.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.93 ' HB ' HG22 ' A' ' 58' ' ' THR . 92.4 t -107.08 137.48 19.56 Favored Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 175.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.451 ' HA ' ' CE1' ' A' ' 57' ' ' PHE . 43.2 Cg_exo -56.9 167.04 3.33 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.863 2.375 . . . . 0.0 113.358 -177.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.66 ' CA ' ' HB2' ' A' ' 56' ' ' PRO . . . -72.38 79.84 0.65 Allowed Glycine 0 N--CA 1.445 -0.731 0 CA-C-N 115.171 -0.922 . . . . 0.0 113.784 -176.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -135.19 142.75 46.14 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 7.2 t -83.94 135.37 24.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.113 0.482 . . . . 0.0 110.745 -173.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' MET . . . . . 0.643 ' HE3' HD12 ' A' ' 123' ' ' LEU . 4.1 ppp? -83.52 179.13 7.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.595 -173.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.584 ' HB3' ' HA ' ' A' ' 107' ' ' GLU . 41.8 m -47.02 -22.86 0.38 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -173.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.7 m -61.67 -15.64 41.82 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.021 0.439 . . . . 0.0 111.072 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -107.05 -51.53 2.9 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.447 0.641 . . . . 0.0 109.677 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 27.9 tp -80.5 -96.69 0.04 OUTLIER 'General case' 0 N--CA 1.438 -1.025 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.612 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.25 149.03 22.36 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 176.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.591 ' HB2' ' H ' ' A' ' 123' ' ' LEU . 0.9 OUTLIER -78.14 130.76 36.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.076 0.465 . . . . 0.0 110.796 -177.428 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.15 59.72 0.44 Allowed Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.661 -176.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.403 ' HE3' ' HA ' ' A' ' 101' ' ' MET . 22.2 ptt? -142.21 171.31 14.23 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 p -112.91 126.25 55.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.694 0.759 . . . . 0.0 111.056 176.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -100.94 138.32 38.13 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.254 -176.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.528 ' O ' HG12 ' A' ' 96' ' ' VAL . 35.6 tt0 -101.64 131.14 48.02 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 120.831 0.348 . . . . 0.0 111.734 -173.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 49.6 p -82.01 155.91 24.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.873 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.24 -33.36 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 123.533 0.521 . . . . 0.0 110.831 179.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.526 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 12.2 tp10 -56.41 -41.88 77.08 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.607 0.718 . . . . 0.0 109.119 174.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.94 53.72 0.22 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-N 114.732 -1.122 . . . . 0.0 111.686 173.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.94 136.15 7.59 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.289 -176.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . 0.402 ' HB2' ' HB ' ' A' ' 110' ' ' THR . . . -96.23 125.2 40.58 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.918 0.389 . . . . 0.0 110.736 -178.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.448 ' O ' ' HA ' ' A' ' 110' ' ' THR . 90.2 mt -109.06 166.08 11.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.968 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.767 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 m -83.29 124.34 30.5 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.253 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 65.5 t -130.55 105.86 11.98 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 79.8 m -140.26 135.11 31.97 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.276 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.643 HD12 ' HE3' ' A' ' 101' ' ' MET . 7.8 mp -102.5 -33.26 9.57 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.521 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -69.92 122.54 19.5 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.272 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.9 3.67 73.31 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.089 -178.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 126.81 118.68 2.21 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -178.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.517 ' HA ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 Cg_endo -67.58 95.12 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.245 1.963 . . . . 0.0 111.567 -178.216 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -126.18 135.06 51.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.794 -172.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.767 ' HA ' ' O ' ' A' ' 120' ' ' THR . 76.3 t -121.96 114.24 42.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 57.9 t30 60.36 15.01 5.1 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.842 178.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.47 12.68 34.91 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.546 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.859 HG12 HD23 ' A' ' 153' ' ' LEU . 4.6 p -124.66 146.72 29.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 174.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 14.0 m -97.57 141.19 30.92 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.652 0.739 . . . . 0.0 112.244 -171.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.447 HD13 HG22 ' A' ' 129' ' ' VAL . 21.4 mt -94.89 77.12 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 169.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . 0.483 ' O ' ' HD3' ' A' ' 137' ' ' PRO . 0.3 OUTLIER -64.23 -27.45 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.51 -170.758 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . 0.467 ' HB2' ' HB ' ' A' ' 148' ' ' VAL . 27.7 mp0 -111.59 85.97 6.47 Favored Pre-proline 0 C--N 1.32 -0.681 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 171.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 135' ' ' SER . 15.7 Cg_exo -70.69 83.38 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 123.024 2.483 . . . . 0.0 112.83 -175.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.4 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.7 t70 -90.42 -159.25 0.59 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 171.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.476 ' O ' HG12 ' A' ' 145' ' ' VAL . 7.2 p 174.75 -50.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 118.445 0.566 . . . . 0.0 112.33 -173.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.403 ' N ' HG11 ' A' ' 139' ' ' VAL . 16.0 t70 -90.33 93.53 9.37 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.914 0.388 . . . . 0.0 112.033 -166.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . 0.469 ' HB2' ' C ' ' A' ' 144' ' ' GLY . . . -89.3 176.55 6.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.981 173.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -78.85 -40.5 32.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.937 0.398 . . . . 0.0 110.529 -173.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -108.23 -33.91 6.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.469 ' C ' ' HB2' ' A' ' 141' ' ' ALA . . . -130.67 -130.9 3.24 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.359 -0.924 . . . . 0.0 113.529 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.844 ' HB ' ' HB ' ' A' ' 58' ' ' THR . 98.4 t -135.55 135.52 51.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.82 0.343 . . . . 0.0 110.314 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 1.7 tp -118.17 129.43 74.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.615 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -136.76 128.29 28.59 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.635 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 92.5 t -91.11 116.75 32.95 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-O 121.394 0.616 . . . . 0.0 111.271 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.761 HG13 ' HB3' ' A' ' 62' ' ' PRO . 8.7 pt -88.77 153.55 3.24 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.627 172.105 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -102.23 5.84 40.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.426 0.631 . . . . 0.0 109.949 174.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . 0.436 ' O ' HD13 ' A' ' 149' ' ' ILE . . . -145.81 -160.23 8.56 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.394 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.42 141.99 43.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.925 0.362 . . . . 0.0 111.258 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.859 HD23 HG12 ' A' ' 132' ' ' VAL . 1.7 pt? -145.65 94.04 2.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.168 0.508 . . . . 0.0 110.781 177.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' MET . . . . . 0.655 ' HG3' ' O ' ' A' ' 153' ' ' LEU . 19.9 mtp -158.02 172.66 5.84 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -177.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 0.486 ' HG2' HD12 ' A' ' 90' ' ' ILE . 50.3 Cg_exo -50.12 -65.48 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.325 0 C-N-CA 122.403 2.069 . . . . 0.0 112.278 -169.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . -126.13 -49.14 0.19 Allowed Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 108.966 -1.654 . . . . 0.0 108.966 170.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . 0.446 ' OXT' ' HE1' ' A' ' 154' ' ' MET . . . . . . . . 0 C--O 1.246 0.905 0 N-CA-C 108.218 -1.031 . . . . 0.0 108.218 169.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 . . . . . 0 N--CA 1.48 1.031 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 93.2 m -145.34 127.95 16.13 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.829 0.347 . . . . 0.0 110.172 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.76 ' HA2' ' HG3' ' A' ' 52' ' ' LYS . . . 113.18 -47.15 1.07 Allowed Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -172.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.3 t0 69.89 -90.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.469 0.708 . . . . 0.0 111.047 168.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.528 ' H ' HD12 ' A' ' 25' ' ' ILE . 3.7 mp -73.37 -48.89 40.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.199 0.523 . . . . 0.0 109.978 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.946 HG11 ' HA ' ' A' ' 48' ' ' VAL . 11.0 m -72.54 -32.36 41.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.17 -172.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 11.3 pt-20 -66.49 -12.99 60.2 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.877 0.37 . . . . 0.0 111.002 -172.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.837 HG21 ' HB3' ' A' ' 39' ' ' LEU . 30.8 m -48.52 -40.82 28.15 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.389 177.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -44.69 -34.71 2.33 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 173.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 m -65.86 -41.04 92.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.053 0.454 . . . . 0.0 110.943 -179.018 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.01 -76.31 1.06 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.597 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.914 ' HB1' ' HA ' ' A' ' 36' ' ' THR . . . 54.32 77.48 0.19 Allowed 'General case' 0 C--O 1.232 0.146 0 C-N-CA 123.148 0.579 . . . . 0.0 111.848 177.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.78 -44.58 1.63 Allowed Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.8 p -89.46 -40.26 12.81 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.294 -0.453 . . . . 0.0 110.4 177.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.515 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 64.7 m-85 -103.36 33.9 3.14 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.296 0.57 . . . . 0.0 110.626 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.914 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . 15.2 t -67.92 -32.06 72.25 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.884 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.2 t -90.19 0.98 56.92 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.887 0.329 . . . . 0.0 111.887 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 67' ' ' PHE . 1.5 tm? -138.97 -66.38 0.47 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 119.988 -0.685 . . . . 0.0 112.395 -175.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.837 ' HB3' HG21 ' A' ' 28' ' ' THR . 12.0 tp -78.91 -12.46 60.03 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -166.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.4 t -60.23 -28.19 67.81 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 109.265 169.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.28 -6.52 58.97 Favored 'General case' 0 C--O 1.215 -0.719 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.825 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.68 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -61.74 -52.98 62.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.391 0.615 . . . . 0.0 109.812 178.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HA ' ' HB ' ' A' ' 48' ' ' VAL . 4.0 tp10 -69.77 -49.39 53.38 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-O 121.321 0.581 . . . . 0.0 109.565 172.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.71 -9.17 58.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 -165.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.704 ' HB3' HD13 ' A' ' 47' ' ' LEU . . . -96.64 3.35 52.56 Favored 'General case' 0 C--N 1.323 -0.563 0 O-C-N 121.957 -0.464 . . . . 0.0 110.443 175.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.58 21.72 49.95 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.969 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.704 HD13 ' HB3' ' A' ' 45' ' ' ALA . 9.9 mp -94.94 -5.95 43.61 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.229 0.538 . . . . 0.0 109.85 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.946 ' HA ' HG11 ' A' ' 26' ' ' VAL . 2.7 p -54.98 -50.91 58.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.392 -0.822 . . . . 0.0 112.194 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 24.1 t70 -63.98 -21.4 66.48 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.053 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.4 m -87.49 -52.99 5.04 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.83 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.456 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 78.1 mt -80.12 -46.97 15.5 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.011 0.434 . . . . 0.0 111.719 -172.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.76 ' HG3' ' HA2' ' A' ' 23' ' ' GLY . 11.7 tttt -93.26 -9.53 38.78 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.332 0.587 . . . . 0.0 110.179 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -85.67 0.41 88.1 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.373 -170.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -132.68 -68.46 0.6 Allowed 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.873 176.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.99 -124.17 1.07 Allowed Glycine 0 N--CA 1.44 -1.077 0 C-N-CA 120.356 -0.926 . . . . 0.0 111.471 -172.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.652 ' HB2' ' CA ' ' A' ' 98' ' ' GLY . 19.5 Cg_endo -60.16 120.75 8.7 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.64 1.56 . . . . 0.0 111.831 -177.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.479 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 9.9 m-85 -149.2 134.81 18.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.238 174.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.92 HG23 ' HB ' ' A' ' 96' ' ' VAL . 0.4 OUTLIER -118.18 122.52 43.22 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.012 -174.384 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 31.1 m -127.99 139.27 52.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.579 -178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -79.86 92.29 5.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.646 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -91.46 112.16 52.77 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.746 ' HB3' HG13 ' A' ' 149' ' ' ILE . 59.8 Cg_endo -80.18 145.41 17.18 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 121.943 1.762 . . . . 0.0 111.64 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.6 t -80.83 171.06 15.49 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.693 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -60.39 -30.02 69.33 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.338 0.59 . . . . 0.0 110.203 178.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.37 -15.32 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.172 178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.96 -36.56 49.01 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.124 0.488 . . . . 0.0 110.47 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.527 ' HE2' ' HB3' ' A' ' 78' ' ' LEU . 14.6 m-85 -68.68 -26.64 65.4 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.634 174.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.38 -13.23 59.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.411 175.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.424 ' C ' ' HD3' ' A' ' 71' ' ' PRO . . . -75.44 -44.26 45.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.118 176.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.462 ' N ' HD23 ' A' ' 70' ' ' LEU . 0.5 OUTLIER -119.27 74.6 15.28 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-O 121.393 0.616 . . . . 0.0 110.334 172.179 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.499 ' HA ' HG12 ' A' ' 75' ' ' VAL . 60.9 Cg_endo -94.62 7.9 2.18 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.386 2.724 . . . . 0.0 113.042 -175.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -57.54 -60.26 3.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.935 0.397 . . . . 0.0 110.371 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.71 -10.35 0.18 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.014 175.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.3 m -71.47 -39.23 71.05 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.831 0.316 . . . . 0.0 110.682 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' A' ' 71' ' ' PRO . 10.2 p -68.34 -31.37 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . 0.595 ' O ' ' HG2' ' A' ' 80' ' ' LYS . 12.2 tp10 -68.11 -46.64 70.37 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -57.83 -47.22 83.28 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.209 0.528 . . . . 0.0 110.39 176.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.527 ' HB3' ' HE2' ' A' ' 67' ' ' PHE . 10.6 mp -77.14 -8.19 57.08 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.684 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 75' ' ' VAL . 28.7 tp -95.31 -21.14 18.6 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.249 0.547 . . . . 0.0 109.812 175.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.595 ' HG2' ' O ' ' A' ' 76' ' ' GLU . 73.1 mmtt -71.96 136.82 82.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.138 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.22 -16.68 18.06 Favored 'Trans proline' 0 N--CA 1.474 0.368 0 C-N-CA 122.99 2.46 . . . . 0.0 112.343 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -65.1 -31.99 73.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.588 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.548 ' O ' ' HG ' ' A' ' 87' ' ' LEU . 4.1 p30 -73.77 -36.58 65.11 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.816 -0.354 . . . . 0.0 111.802 -170.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.455 ' HA ' HD12 ' A' ' 87' ' ' LEU . 14.7 pttm -68.14 -25.56 65.34 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.997 -176.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' THR . 5.0 mm-40 -69.84 -39.44 76.42 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.816 178.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.464 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 12.1 ptmm? -81.08 -23.31 38.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.895 178.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.548 ' HG ' ' O ' ' A' ' 83' ' ' ASN . 57.2 mt -61.41 -35.69 78.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 171.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.542 ' O ' HD22 ' A' ' 91' ' ' LEU . 51.7 m -54.4 -42.65 70.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.18 0.514 . . . . 0.0 110.355 172.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -74.11 -44.02 55.39 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.718 178.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.505 HD11 ' HG2' ' A' ' 155' ' ' PRO . 1.5 tp -97.77 2.61 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.882 -162.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.542 HD22 ' O ' ' A' ' 88' ' ' THR . 2.5 pt? -49.98 -37.04 30.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.971 -176.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.538 ' HB ' ' CA ' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -61.02 -26.12 67.39 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.355 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.513 ' CD2' ' HA ' ' A' ' 154' ' ' MET . 41.2 t80 -94.34 -6.98 43.08 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.421 0.629 . . . . 0.0 110.333 -178.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -106.93 -21.85 12.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.585 0.707 . . . . 0.0 109.17 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.403 ' O ' HG23 ' A' ' 114' ' ' VAL . 93.4 t -96.88 121.12 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.778 176.419 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.92 ' HB ' HG23 ' A' ' 58' ' ' THR . 92.4 t -107.08 137.48 19.56 Favored Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 175.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HA ' ' CE1' ' A' ' 57' ' ' PHE . 43.2 Cg_exo -56.9 167.04 3.33 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.863 2.375 . . . . 0.0 113.358 -177.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.652 ' CA ' ' HB2' ' A' ' 56' ' ' PRO . . . -72.38 79.84 0.65 Allowed Glycine 0 N--CA 1.445 -0.731 0 CA-C-N 115.171 -0.922 . . . . 0.0 113.784 -176.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -135.19 142.75 46.14 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 7.2 t -83.94 135.37 24.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.113 0.482 . . . . 0.0 110.745 -173.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -83.52 179.13 7.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.595 -173.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.579 ' HB3' ' HA ' ' A' ' 107' ' ' GLU . 41.8 m -47.02 -22.86 0.38 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -173.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.7 m -61.67 -15.64 41.82 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.021 0.439 . . . . 0.0 111.072 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -107.05 -51.53 2.9 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.447 0.641 . . . . 0.0 109.677 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 27.9 tp -80.5 -96.69 0.04 OUTLIER 'General case' 0 N--CA 1.438 -1.025 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.612 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.25 149.03 22.36 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 176.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.668 ' HB2' ' H ' ' A' ' 123' ' ' LEU . 0.9 OUTLIER -78.14 130.76 36.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.076 0.465 . . . . 0.0 110.796 -177.428 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.15 59.72 0.44 Allowed Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.661 -176.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 22.2 ptt? -142.21 171.31 14.23 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 p -112.91 126.25 55.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.694 0.759 . . . . 0.0 111.056 176.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -100.94 138.32 38.13 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.254 -176.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.539 ' O ' HG13 ' A' ' 96' ' ' VAL . 35.6 tt0 -101.64 131.14 48.02 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 120.831 0.348 . . . . 0.0 111.734 -173.198 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 49.6 p -82.01 155.91 24.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.873 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 95' ' ' VAL . 60.0 t -60.24 -33.36 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 123.533 0.521 . . . . 0.0 110.831 179.224 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.538 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 12.2 tp10 -56.41 -41.88 77.08 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.607 0.718 . . . . 0.0 109.119 174.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.94 53.72 0.22 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-N 114.732 -1.122 . . . . 0.0 111.686 173.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.94 136.15 7.59 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.289 -176.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 110' ' ' THR . . . -96.23 125.2 40.58 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.918 0.389 . . . . 0.0 110.736 -178.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.45 HD13 HD12 ' A' ' 153' ' ' LEU . 90.2 mt -109.06 166.08 11.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.968 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.771 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 m -83.29 124.34 30.5 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.253 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 65.5 t -130.55 105.86 11.98 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 79.8 m -140.26 135.11 31.97 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.276 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.668 ' H ' ' HB2' ' A' ' 107' ' ' GLU . 7.8 mp -102.5 -33.26 9.57 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.521 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -69.92 122.54 19.5 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.272 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.9 3.67 73.31 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.089 -178.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 126.81 118.68 2.21 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -178.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 Cg_endo -67.58 95.12 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.245 1.963 . . . . 0.0 111.567 -178.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -126.18 135.06 51.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.794 -172.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.771 ' HA ' ' O ' ' A' ' 120' ' ' THR . 76.3 t -121.96 114.24 42.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.404 ' H ' ' HB ' ' A' ' 120' ' ' THR . 57.9 t30 60.36 15.01 5.1 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.842 178.129 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.47 12.68 34.91 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.546 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.878 HG11 HD22 ' A' ' 153' ' ' LEU . 4.6 p -124.66 146.72 29.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 174.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 14.0 m -97.57 141.19 30.92 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.652 0.739 . . . . 0.0 112.244 -171.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.425 HD11 HG21 ' A' ' 129' ' ' VAL . 21.4 mt -94.89 77.12 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 169.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.498 ' O ' ' HD3' ' A' ' 137' ' ' PRO . 0.3 OUTLIER -64.23 -27.45 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.51 -170.758 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 148' ' ' VAL . 27.7 mp0 -111.59 85.97 6.47 Favored Pre-proline 0 C--N 1.32 -0.681 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 171.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' PRO . . . . . 0.498 ' HD3' ' O ' ' A' ' 135' ' ' SER . 15.7 Cg_exo -70.69 83.38 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 123.024 2.483 . . . . 0.0 112.83 -175.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.417 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.7 t70 -90.42 -159.25 0.59 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 171.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.484 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.2 p 174.75 -50.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 118.445 0.566 . . . . 0.0 112.33 -173.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -90.33 93.53 9.37 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.914 0.388 . . . . 0.0 112.033 -166.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.486 ' HB3' ' C ' ' A' ' 144' ' ' GLY . . . -89.3 176.55 6.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.981 173.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -78.85 -40.5 32.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.937 0.398 . . . . 0.0 110.529 -173.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.404 HD22 ' HA ' ' A' ' 52' ' ' LYS . 64.4 t30 -108.23 -33.91 6.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.187 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.486 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . -130.67 -130.9 3.24 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.359 -0.924 . . . . 0.0 113.529 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.871 ' HB ' ' HB ' ' A' ' 58' ' ' THR . 98.4 t -135.55 135.52 51.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.82 0.343 . . . . 0.0 110.314 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 1.7 tp -118.17 129.43 74.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.615 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -136.76 128.29 28.59 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.646 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 92.5 t -91.11 116.75 32.95 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-O 121.394 0.616 . . . . 0.0 111.271 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.746 HG13 ' HB3' ' A' ' 62' ' ' PRO . 8.7 pt -88.77 153.55 3.24 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.627 172.105 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -102.23 5.84 40.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.426 0.631 . . . . 0.0 109.949 174.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.438 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -145.81 -160.23 8.56 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.394 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.42 141.99 43.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.925 0.362 . . . . 0.0 111.258 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.878 HD22 HG11 ' A' ' 132' ' ' VAL . 1.7 pt? -145.65 94.04 2.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.168 0.508 . . . . 0.0 110.781 177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.652 ' HG3' ' O ' ' A' ' 153' ' ' LEU . 19.9 mtp -158.02 172.66 5.84 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -177.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.505 ' HG2' HD11 ' A' ' 90' ' ' ILE . 50.3 Cg_exo -50.12 -65.48 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.325 0 C-N-CA 122.403 2.069 . . . . 0.0 112.278 -169.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . -126.13 -49.14 0.19 Allowed Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 108.966 -1.654 . . . . 0.0 108.966 170.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.905 0 N-CA-C 108.218 -1.031 . . . . 0.0 108.218 169.087 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 . . . . . 0 N--CA 1.48 1.031 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 93.2 m -145.34 127.95 16.13 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.829 0.347 . . . . 0.0 110.172 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.76 ' HA2' ' HG3' ' A' ' 52' ' ' LYS . . . 113.18 -47.15 1.07 Allowed Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 -172.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.3 t0 69.89 -90.06 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.469 0.708 . . . . 0.0 111.047 168.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.528 ' H ' HD12 ' A' ' 25' ' ' ILE . 3.7 mp -73.37 -48.89 40.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.199 0.523 . . . . 0.0 109.978 176.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.946 HG11 ' HA ' ' A' ' 48' ' ' VAL . 11.0 m -72.54 -32.36 41.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.17 -172.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' HB3' ' HA3' ' A' ' 23' ' ' GLY . 11.3 pt-20 -66.49 -12.99 60.2 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.877 0.37 . . . . 0.0 111.002 -172.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.837 HG21 ' HB3' ' A' ' 39' ' ' LEU . 30.8 m -48.52 -40.82 28.15 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.389 177.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.497 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -44.69 -34.71 2.33 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 113.055 0.761 . . . . 0.0 113.055 173.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 m -65.86 -41.04 92.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.053 0.454 . . . . 0.0 110.943 -179.018 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -105.01 -76.31 1.06 Allowed Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.597 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.914 ' HB1' ' HA ' ' A' ' 36' ' ' THR . . . 54.32 77.48 0.19 Allowed 'General case' 0 C--O 1.232 0.146 0 C-N-CA 123.148 0.579 . . . . 0.0 111.848 177.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.78 -44.58 1.63 Allowed Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 11.8 p -89.46 -40.26 12.81 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.294 -0.453 . . . . 0.0 110.4 177.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.515 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 64.7 m-85 -103.36 33.9 3.14 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 121.296 0.57 . . . . 0.0 110.626 -177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.914 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . 15.2 t -67.92 -32.06 72.25 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.362 -0.836 . . . . 0.0 111.884 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.2 t -90.19 0.98 56.92 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.887 0.329 . . . . 0.0 111.887 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 67' ' ' PHE . 1.5 tm? -138.97 -66.38 0.47 Allowed 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 119.988 -0.685 . . . . 0.0 112.395 -175.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.837 ' HB3' HG21 ' A' ' 28' ' ' THR . 12.0 tp -78.91 -12.46 60.03 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -166.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.4 t -60.23 -28.19 67.81 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.727 0.775 . . . . 0.0 109.265 169.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -81.28 -6.52 58.97 Favored 'General case' 0 C--O 1.215 -0.719 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.825 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.68 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -61.74 -52.98 62.04 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.391 0.615 . . . . 0.0 109.812 178.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HA ' ' HB ' ' A' ' 48' ' ' VAL . 4.0 tp10 -69.77 -49.39 53.38 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-O 121.321 0.581 . . . . 0.0 109.565 172.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.71 -9.17 58.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 114.557 1.317 . . . . 0.0 114.557 -165.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.704 ' HB3' HD13 ' A' ' 47' ' ' LEU . . . -96.64 3.35 52.56 Favored 'General case' 0 C--N 1.323 -0.563 0 O-C-N 121.957 -0.464 . . . . 0.0 110.443 175.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 86.58 21.72 49.95 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.969 -178.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.704 HD13 ' HB3' ' A' ' 45' ' ' ALA . 9.9 mp -94.94 -5.95 43.61 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.229 0.538 . . . . 0.0 109.85 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.946 ' HA ' HG11 ' A' ' 26' ' ' VAL . 2.7 p -54.98 -50.91 58.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.392 -0.822 . . . . 0.0 112.194 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.493 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 24.1 t70 -63.98 -21.4 66.48 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.053 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.4 m -87.49 -52.99 5.04 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.83 -175.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.456 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 78.1 mt -80.12 -46.97 15.5 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.011 0.434 . . . . 0.0 111.719 -172.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.76 ' HG3' ' HA2' ' A' ' 23' ' ' GLY . 11.7 tttt -93.26 -9.53 38.78 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.332 0.587 . . . . 0.0 110.179 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -85.67 0.41 88.1 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.735 -0.745 . . . . 0.0 113.373 -170.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -132.68 -68.46 0.6 Allowed 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.873 176.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.99 -124.17 1.07 Allowed Glycine 0 N--CA 1.44 -1.077 0 C-N-CA 120.356 -0.926 . . . . 0.0 111.471 -172.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.652 ' HB2' ' CA ' ' A' ' 98' ' ' GLY . 19.5 Cg_endo -60.16 120.75 8.7 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.64 1.56 . . . . 0.0 111.831 -177.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.479 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 9.9 m-85 -149.2 134.81 18.64 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.238 174.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.92 HG23 ' HB ' ' A' ' 96' ' ' VAL . 0.4 OUTLIER -118.18 122.52 43.22 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.323 -0.853 . . . . 0.0 111.012 -174.384 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 31.1 m -127.99 139.27 52.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.579 -178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 39.5 m-85 -79.86 92.29 5.47 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.646 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -91.46 112.16 52.77 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.746 ' HB3' HG13 ' A' ' 149' ' ' ILE . 59.8 Cg_endo -80.18 145.41 17.18 Favored 'Trans proline' 0 N--CA 1.453 -0.882 0 C-N-CA 121.943 1.762 . . . . 0.0 111.64 179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.6 t -80.83 171.06 15.49 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.693 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -60.39 -30.02 69.33 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.338 0.59 . . . . 0.0 110.203 178.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.37 -15.32 59.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.172 178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.96 -36.56 49.01 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.124 0.488 . . . . 0.0 110.47 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.527 ' HE2' ' HB3' ' A' ' 78' ' ' LEU . 14.6 m-85 -68.68 -26.64 65.4 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.634 174.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.38 -13.23 59.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.411 175.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.424 ' C ' ' HD3' ' A' ' 71' ' ' PRO . . . -75.44 -44.26 45.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.118 176.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.462 ' N ' HD23 ' A' ' 70' ' ' LEU . 0.5 OUTLIER -119.27 74.6 15.28 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-O 121.393 0.616 . . . . 0.0 110.334 172.179 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.499 ' HA ' HG12 ' A' ' 75' ' ' VAL . 60.9 Cg_endo -94.62 7.9 2.18 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 123.386 2.724 . . . . 0.0 113.042 -175.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -57.54 -60.26 3.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.935 0.397 . . . . 0.0 110.371 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.71 -10.35 0.18 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.547 -0.835 . . . . 0.0 113.014 175.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.3 m -71.47 -39.23 71.05 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 116.831 0.316 . . . . 0.0 110.682 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.499 HG12 ' HA ' ' A' ' 71' ' ' PRO . 10.2 p -68.34 -31.37 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . 0.595 ' O ' ' HG2' ' A' ' 80' ' ' LYS . 12.2 tp10 -68.11 -46.64 70.37 Favored 'General case' 0 N--CA 1.447 -0.614 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 60.0 m-20 -57.83 -47.22 83.28 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.209 0.528 . . . . 0.0 110.39 176.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.527 ' HB3' ' HE2' ' A' ' 67' ' ' PHE . 10.6 mp -77.14 -8.19 57.08 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.684 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.435 ' HB2' ' O ' ' A' ' 75' ' ' VAL . 28.7 tp -95.31 -21.14 18.6 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.249 0.547 . . . . 0.0 109.812 175.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.595 ' HG2' ' O ' ' A' ' 76' ' ' GLU . 73.1 mmtt -71.96 136.82 82.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.138 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.22 -16.68 18.06 Favored 'Trans proline' 0 N--CA 1.474 0.368 0 C-N-CA 122.99 2.46 . . . . 0.0 112.343 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -65.1 -31.99 73.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.307 -0.86 . . . . 0.0 111.588 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.548 ' O ' ' HG ' ' A' ' 87' ' ' LEU . 4.1 p30 -73.77 -36.58 65.11 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.816 -0.354 . . . . 0.0 111.802 -170.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.455 ' HA ' HD12 ' A' ' 87' ' ' LEU . 14.7 pttm -68.14 -25.56 65.34 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.331 -0.548 . . . . 0.0 109.997 -176.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.418 ' O ' ' HB ' ' A' ' 88' ' ' THR . 5.0 mm-40 -69.84 -39.44 76.42 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.816 178.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.464 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 12.1 ptmm? -81.08 -23.31 38.55 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.895 178.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.548 ' HG ' ' O ' ' A' ' 83' ' ' ASN . 57.2 mt -61.41 -35.69 78.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 171.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.542 ' O ' HD22 ' A' ' 91' ' ' LEU . 51.7 m -54.4 -42.65 70.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.18 0.514 . . . . 0.0 110.355 172.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 -74.11 -44.02 55.39 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.718 178.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.505 HD11 ' HG2' ' A' ' 155' ' ' PRO . 1.5 tp -97.77 2.61 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.882 -162.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.542 HD22 ' O ' ' A' ' 88' ' ' THR . 2.5 pt? -49.98 -37.04 30.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.971 -176.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.538 ' HB ' ' CA ' ' A' ' 115' ' ' GLU . 0.2 OUTLIER -61.02 -26.12 67.39 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.355 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.513 ' CD2' ' HA ' ' A' ' 154' ' ' MET . 41.2 t80 -94.34 -6.98 43.08 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.421 0.629 . . . . 0.0 110.333 -178.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -106.93 -21.85 12.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.585 0.707 . . . . 0.0 109.17 178.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.403 ' O ' HG23 ' A' ' 114' ' ' VAL . 93.4 t -96.88 121.12 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.778 176.419 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.92 ' HB ' HG23 ' A' ' 58' ' ' THR . 92.4 t -107.08 137.48 19.56 Favored Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 175.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.462 ' HA ' ' CE1' ' A' ' 57' ' ' PHE . 43.2 Cg_exo -56.9 167.04 3.33 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.863 2.375 . . . . 0.0 113.358 -177.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.652 ' CA ' ' HB2' ' A' ' 56' ' ' PRO . . . -72.38 79.84 0.65 Allowed Glycine 0 N--CA 1.445 -0.731 0 CA-C-N 115.171 -0.922 . . . . 0.0 113.784 -176.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.4 tp10 -135.19 142.75 46.14 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 177.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 7.2 t -83.94 135.37 24.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.113 0.482 . . . . 0.0 110.745 -173.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -83.52 179.13 7.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.595 -173.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.579 ' HB3' ' HA ' ' A' ' 107' ' ' GLU . 41.8 m -47.02 -22.86 0.38 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 114.887 1.44 . . . . 0.0 114.887 -173.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 50.7 m -61.67 -15.64 41.82 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.021 0.439 . . . . 0.0 111.072 176.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -107.05 -51.53 2.9 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.447 0.641 . . . . 0.0 109.677 177.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 27.9 tp -80.5 -96.69 0.04 OUTLIER 'General case' 0 N--CA 1.438 -1.025 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.612 -177.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.25 149.03 22.36 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 176.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.668 ' HB2' ' H ' ' A' ' 123' ' ' LEU . 0.9 OUTLIER -78.14 130.76 36.75 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.076 0.465 . . . . 0.0 110.796 -177.428 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.15 59.72 0.44 Allowed Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.661 -176.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 22.2 ptt? -142.21 171.31 14.23 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 p -112.91 126.25 55.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.694 0.759 . . . . 0.0 111.056 176.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -100.94 138.32 38.13 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.254 -176.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.539 ' O ' HG13 ' A' ' 96' ' ' VAL . 35.6 tt0 -101.64 131.14 48.02 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 120.831 0.348 . . . . 0.0 111.734 -173.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 49.6 p -82.01 155.91 24.92 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.873 176.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 95' ' ' VAL . 60.0 t -60.24 -33.36 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 O-C-N 123.533 0.521 . . . . 0.0 110.831 179.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.538 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 12.2 tp10 -56.41 -41.88 77.08 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.607 0.718 . . . . 0.0 109.119 174.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.94 53.72 0.22 Allowed Glycine 0 N--CA 1.443 -0.841 0 CA-C-N 114.732 -1.122 . . . . 0.0 111.686 173.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -139.94 136.15 7.59 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.252 -0.975 . . . . 0.0 112.289 -176.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.431 ' HB1' ' HB ' ' A' ' 110' ' ' THR . . . -96.23 125.2 40.58 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.918 0.389 . . . . 0.0 110.736 -178.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.45 HD13 HD12 ' A' ' 153' ' ' LEU . 90.2 mt -109.06 166.08 11.1 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.968 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.771 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 m -83.29 124.34 30.5 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.253 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 65.5 t -130.55 105.86 11.98 Favored 'Isoleucine or valine' 0 C--O 1.235 0.294 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 79.8 m -140.26 135.11 31.97 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.276 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.668 ' H ' ' HB2' ' A' ' 107' ' ' GLU . 7.8 mp -102.5 -33.26 9.57 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.521 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -69.92 122.54 19.5 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.272 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.9 3.67 73.31 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.089 -178.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 126.81 118.68 2.21 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -178.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 Cg_endo -67.58 95.12 0.39 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.245 1.963 . . . . 0.0 111.567 -178.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 22.8 ttmm -126.18 135.06 51.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.794 -172.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.771 ' HA ' ' O ' ' A' ' 120' ' ' THR . 76.3 t -121.96 114.24 42.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.404 ' H ' ' HB ' ' A' ' 120' ' ' THR . 57.9 t30 60.36 15.01 5.1 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.842 178.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.47 12.68 34.91 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.546 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.878 HG11 HD22 ' A' ' 153' ' ' LEU . 4.6 p -124.66 146.72 29.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 174.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 14.0 m -97.57 141.19 30.92 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.652 0.739 . . . . 0.0 112.244 -171.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.425 HD11 HG21 ' A' ' 129' ' ' VAL . 21.4 mt -94.89 77.12 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 169.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.498 ' O ' ' HD3' ' A' ' 137' ' ' PRO . 0.3 OUTLIER -64.23 -27.45 69.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.51 -170.758 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 148' ' ' VAL . 27.7 mp0 -111.59 85.97 6.47 Favored Pre-proline 0 C--N 1.32 -0.681 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 171.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . 0.498 ' HD3' ' O ' ' A' ' 135' ' ' SER . 15.7 Cg_exo -70.69 83.38 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 123.024 2.483 . . . . 0.0 112.83 -175.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.417 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.7 t70 -90.42 -159.25 0.59 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 171.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.484 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.2 p 174.75 -50.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 118.445 0.566 . . . . 0.0 112.33 -173.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -90.33 93.53 9.37 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 120.914 0.388 . . . . 0.0 112.033 -166.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.486 ' HB3' ' C ' ' A' ' 144' ' ' GLY . . . -89.3 176.55 6.89 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.981 173.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 9.7 t -78.85 -40.5 32.5 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.937 0.398 . . . . 0.0 110.529 -173.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.404 HD22 ' HA ' ' A' ' 52' ' ' LYS . 64.4 t30 -108.23 -33.91 6.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.486 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . -130.67 -130.9 3.24 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.359 -0.924 . . . . 0.0 113.529 -176.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.871 ' HB ' ' HB ' ' A' ' 58' ' ' THR . 98.4 t -135.55 135.52 51.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.82 0.343 . . . . 0.0 110.314 -174.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 1.7 tp -118.17 129.43 74.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.615 -175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -136.76 128.29 28.59 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 174.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.646 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 92.5 t -91.11 116.75 32.95 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-O 121.394 0.616 . . . . 0.0 111.271 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.746 HG13 ' HB3' ' A' ' 62' ' ' PRO . 8.7 pt -88.77 153.55 3.24 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.627 172.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -102.23 5.84 40.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.426 0.631 . . . . 0.0 109.949 174.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.438 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -145.81 -160.23 8.56 Favored Glycine 0 N--CA 1.446 -0.652 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.394 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.42 141.99 43.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.925 0.362 . . . . 0.0 111.258 -178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.878 HD22 HG11 ' A' ' 132' ' ' VAL . 1.7 pt? -145.65 94.04 2.44 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.168 0.508 . . . . 0.0 110.781 177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.652 ' HG3' ' O ' ' A' ' 153' ' ' LEU . 19.9 mtp -158.02 172.66 5.84 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -177.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.505 ' HG2' HD11 ' A' ' 90' ' ' ILE . 50.3 Cg_exo -50.12 -65.48 0.15 Allowed 'Trans proline' 0 C--N 1.363 1.325 0 C-N-CA 122.403 2.069 . . . . 0.0 112.278 -169.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . -126.13 -49.14 0.19 Allowed Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 108.966 -1.654 . . . . 0.0 108.966 170.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.905 0 N-CA-C 108.218 -1.031 . . . . 0.0 108.218 169.087 . . . . . . . . 0 0 . 1 stop_ save_